CrystalGenomics "ASCO to Present 'Camrelizumab' Research Results"

CrystalGenomics announced on the 18th that it will disclose the research results on the indications of the immuno-oncology drug 'Camrelizumab' at the American Society of Clinical Oncology (ASCO 2023), held in Chicago, USA, from the 2nd to the 6th of next month.

CrystalGenomics logo. [Image provided by CrystalGenomics]

According to its partner, Hansoh Pharmaceutical, the main research results of Camrelizumab to be revealed at this ASCO include ▲ preliminary Phase 2 clinical trial results of Camrelizumab combined with Vinorelbine as a first-line treatment for non-small cell lung cancer (NSCLC) patients aged 70 and above ▲ Phase 2/3 clinical trial results of Camrelizumab combined with Apatinib as preoperative treatment for resectable hepatocellular carcinoma (HCC) in moderate to high-risk recurrence patients. In addition, investigator-initiated clinical results on multiple indications related to Camrelizumab, such as gastric cancer, renal cancer, and breast cancer, will also be presented in poster format.

A representative from CrystalGenomics stated, "Based on the 40 Camrelizumab research results to be disclosed at this ASCO, we plan to discuss indication expansion and development priorities together with Hansoh Pharmaceutical."

Meanwhile, the bridging clinical trial for domestic approval of Camrelizumab for non-small cell lung cancer is currently undergoing Institutional Review Board (IRB) approval processes at each hospital. Two IRB approvals have been obtained so far, and the first patient injection (FPI) is scheduled to begin within June.

This content was produced with the assistance of AI translation services.